Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Simplified Regimen to Prevent Nausea and Vomiting Using Netupitant/Palonosetron in Germ Cell Cancer Patients Receiving Chemotherapy
Sponsor: Ottawa Hospital Research Institute
Summary
This is a single-site, open-label, randomized pilot feasibility study conducted at The Ottawa Hospital Cancer Centre. A total of 10 participants will be randomized 1:1 to either the experimental or control arm. The purpose of this study is to evaluate recruitment capability, intervention adherence, data completeness, and safety prior to consideration of a potential future multi-centre randomized trial.
Official title: A Pilot Feasibility Study of a Steroid-Sparing Anti-Nausea and Vomiting Regimen With Netupitant/Palonosetron for Patients With Germ Cell Tumours Receiving Multi-Day Cisplatin-Based Chemotherapy at The Ottawa Hospital
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-08
Completion Date
2028-08
Last Updated
2026-06-23
Healthy Volunteers
No
Conditions
Interventions
Netupitant/Palonosetron Hydrochloride
300mg/0.5mg combination pill taken once daily by mouth on the first and third day of chemotherapy
Ondansetron (Control)
8mg taken twice daily by mouth for 5 days
Aprepitant
Daily by mouth on the first (125mg), third (80mg), and fifth (80mg) day
Dexamethasone
Daily by mouth for 7 days (12mg on the first day, 8mg on subsequent days)
Olanzapine
5mg taken at night by mouth for 7 days
Locations (1)
Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada